Deal-Making Trends
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline
Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.
Dealmaking Quarterly Statistics, Q1 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.
BioBytes: AI-Related Deals In Q1 2024
BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
Deals in Depth: March 2024
Two $1bn+ alliances were penned in March. In the top alliance by deal value, Merus NV will use its Triclonics anitbody platform to discover new dual tumor-associated antigens targeting trispecific antibodies for Gilead Sciences. Merus will lead early-stage research activities for two programs, with an option to pursue a third. Gilead will have the right to license programs developed under the collaboration after the completion of select research activities. If Gilead exercises its option to license any such program from the collaboration, Gilead will be responsible for additional research, development and commercialization activities for such program. The deal could be worth up to $1.5bn for Merus.
NVIDIA Extends Its Biopharma Tentacles
NVIDIA is further embedding itself in the biopharma industry. Its artificial intelligence tools are now more accessible, integrated and it is taking a strategic collaborative approach with competitors like Google to bolster AI-driven startups that ultimately use its tools.
A Snapshot of Updates In The APAC Region
US-China tensions, the increasing importance of Singapore as a doorway to the Asia-Pacific region, growing AI innovation in South Korea and a changing clinical trials landscape in Japan are just some of the recent developments in APAC.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
Investing Is A People Business, Says LifeArc’s Clare Terlouw
Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.